Limaye Nisha, Wouters Vinciane, Uebelhoer Melanie, Tuominen Marjut, Wirkkala Riikka, Mulliken John B, Eklund Lauri, Boon Laurence M, Vikkula Miikka
de Duve Institute, Université catholique de Louvain, Brussels, Belgium.
Nat Genet. 2009 Jan;41(1):118-24. doi: 10.1038/ng.272. Epub 2008 Dec 14.
Germline substitutions in the endothelial cell tyrosine kinase receptor TIE2 (encoded by TEK) cause a rare, inherited form of venous anomaly known as a mucocutaneous venous malformation (VMCM; refs. 1, 2, 3 and V.W., N.L., M.U., A. Irrthum, L.M.B. et al., unpublished data). We identified a somatic 'second hit' causing loss of function of TIE2 in a resected VMCM and assessed whether such localized, tissue-specific events have a role in the etiology of sporadic venous malformations, which are far more common. We identified eight somatic TEK mutations in lesions from 28 of 57 individuals (49.1%) with sporadic venous malformations; the mutations were absent from the individuals' blood and control tissues. The somatic mutations included one causing a frequent L914F substitution and several double mutations in cis, all of which resulted in ligand-independent TIE2 hyperphosphorylation in vitro. When overexpressed in human umbilical vein endothelial cells, the L914F mutant was abnormally localized and responded to ligand, in contrast to wild-type TIE2 and the common, inherited R849W mutant, suggesting that the mutations have distinct effects. The presence of the same mutations in multifocal sporadic venous malformations in two individuals suggests a common origin for the abnormal endothelial cells at the distant sites. These data show that a sporadic disease may be explained by somatic changes in a gene causing rare, inherited forms and pinpoint TIE2 pathways as potential therapeutic targets for venous malformations.
内皮细胞酪氨酸激酶受体TIE2(由TEK编码)中的种系替代导致一种罕见的遗传性静脉畸形,称为黏膜皮肤静脉畸形(VMCM;参考文献1、2、3以及V.W.、N.L.、M.U.、A. Irrthum、L.M.B.等人未发表的数据)。我们在一例切除的VMCM中发现了导致TIE2功能丧失的体细胞“二次打击”,并评估了这种局部性、组织特异性事件在散发性静脉畸形病因中的作用,散发性静脉畸形更为常见。我们在57例散发性静脉畸形患者中的28例(49.1%)的病变中发现了8种体细胞TEK突变;这些突变在患者的血液和对照组织中不存在。体细胞突变包括一个导致常见的L914F替代的突变以及几个顺式双突变,所有这些突变在体外均导致不依赖配体的TIE2过度磷酸化。与野生型TIE2和常见的遗传性R849W突变体相比,当在人脐静脉内皮细胞中过表达时,L914F突变体定位异常且对配体有反应,这表明这些突变具有不同的作用。两名患者多灶性散发性静脉畸形中存在相同的突变,这表明远处部位异常内皮细胞有共同起源。这些数据表明,一种散发性疾病可能由导致罕见遗传性形式的基因中的体细胞变化来解释,并确定TIE2通路是静脉畸形的潜在治疗靶点。